Financial - Capital Markets
Build Your Comparison
Side-by-side financial analysisStock Comparison
NAKA vs DOCS vs HIMS vs WELL vs JPM vs KO
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Information Services
Medical - Equipment & Services
REIT - Healthcare Facilities
Banks - Diversified
Beverages - Non-Alcoholic
NAKA vs DOCS vs HIMS vs WELL vs JPM vs KO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||||
|---|---|---|---|---|---|---|
| Industry | Financial - Capital Markets | Medical - Healthcare Information Services | Medical - Equipment & Services | REIT - Healthcare Facilities | Banks - Diversified | Beverages - Non-Alcoholic |
| Market Cap | $79M | $3.87B | $6.62B | $149.11B | $892.31B | $348.25B |
| Revenue (TTM) | $4M | $645M | $2.37B | $11.63B | $280.33B | $49.28B |
| Net Income (TTM) | $-290M | $196M | $-13M | $1.43B | $57.05B | $13.70B |
| Gross Margin | -376.0% | 89.1% | 67.6% | 39.1% | 60.0% | 61.7% |
| Operating Margin | -82.2% | 33.3% | 1.3% | 4.4% | 25.9% | 29.3% |
| Forward P/E | — | 14.4x | 59.2x | 73.5x | 14.3x | 24.7x |
| Total Debt | $210M | $10M | $1.26B | $21.38B | $942.38B | $45.49B |
| Cash & Equiv. | $23M | $219M | $229M | $5.03B | $343.34B | $10.27B |
NAKA vs DOCS vs HIMS vs WELL vs JPM vs KO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 24 | Jun 26 | Return |
|---|---|---|---|
| Nakamoto Inc. (NAKA) | 100 | 3.7 | -96.3% |
| Doximity, Inc. (DOCS) | 100 | 74.6 | -25.4% |
| Hims & Hers Health,… (HIMS) | 100 | 155.4 | +55.4% |
| Welltower Inc. (WELL) | 100 | 205.3 | +105.3% |
| JPMorgan Chase & Co. (JPM) | 100 | 157.6 | +57.6% |
| The Coca-Cola Compa… (KO) | 100 | 128.6 | +28.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NAKA vs DOCS vs HIMS vs WELL vs JPM vs KO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NAKA doesn't hold a clear category lead here; it's more of a secondary option in this specific comparison.
DOCS has the current edge in this matchup, primarily because of its strength in sleep-well-at-night and valuation efficiency.
- Lower volatility, beta 0.75, Low D/E 1.1%, current ratio 6.09x
- PEG 0.28 vs KO's 2.21
- 30.4% margin vs NAKA's -74.0%
- 16.5% ROA vs NAKA's -56.5%, ROIC 19.8% vs -42.1%
HIMS ranks third and is worth considering specifically for growth exposure.
- Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
- 59.0% revenue growth vs NAKA's -33.0%
WELL is the #2 pick in this set and the best alternative if long-term compounding and defensive is your priority.
- 229.1% 10Y total return vs JPM's 475.6%
- Beta 0.04, yield 1.3%, current ratio 5.34x
- Beta 0.04 vs NAKA's 2.88
- +43.3% vs NAKA's -99.3%
JPM is the clearest fit if your priority is value.
- Lower P/E (14.3x vs 24.7x), PEG 0.81 vs 2.21
KO is the clearest fit if your priority is income & stability.
- Dividend streak 56 yrs, beta -0.20, yield 2.5%
- 2.5% yield, 56-year raise streak, vs JPM's 1.9%, (3 stocks pay no dividend)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 59.0% revenue growth vs NAKA's -33.0% | |
| Value | Lower P/E (14.3x vs 24.7x), PEG 0.81 vs 2.21 | |
| Quality / Margins | 30.4% margin vs NAKA's -74.0% | |
| Stability / Safety | Beta 0.04 vs NAKA's 2.88 | |
| Dividends | 2.5% yield, 56-year raise streak, vs JPM's 1.9%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +43.3% vs NAKA's -99.3% | |
| Efficiency (ROA) | 16.5% ROA vs NAKA's -56.5%, ROIC 19.8% vs -42.1% |
NAKA vs DOCS vs HIMS vs WELL vs JPM vs KO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
NAKA vs DOCS vs HIMS vs WELL vs JPM vs KO — Financial Metrics
Side-by-side numbers across 6 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
DOCS leads in 2 of 6 categories
KO leads 2 • NAKA leads 0 • HIMS leads 0 • WELL leads 0 • JPM leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
DOCS leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 71519.7x NAKA's $4M. DOCS is the more profitable business, keeping 30.4% of every revenue dollar as net income compared to NAKA's -74.0%.
| Metric | ||||||
|---|---|---|---|---|---|---|
| RevenueTrailing 12 months | $4M | $645M | $2.4B | $11.6B | $280.3B | $49.3B |
| EBITDAEarnings before interest/tax | -$320M | $227M | $99M | $2.8B | $81.4B | $15.5B |
| Net IncomeAfter-tax profit | -$290M | $196M | -$13M | $1.4B | $57.0B | $13.7B |
| Free Cash FlowCash after capex | -$46M | $215M | $76M | $2.5B | $100.9B | $12.6B |
| Gross MarginGross profit ÷ Revenue | -3.8% | +89.1% | +67.6% | +39.1% | +60.0% | +61.7% |
| Operating MarginEBIT ÷ Revenue | -82.2% | +33.3% | +1.3% | +4.4% | +25.9% | +29.3% |
| Net MarginNet income ÷ Revenue | -74.0% | +30.4% | -0.6% | +12.3% | +20.4% | +27.8% |
| FCF MarginFCF ÷ Revenue | -11.7% | +33.3% | +3.2% | +21.9% | +36.0% | +25.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.6% | +5.1% | +3.8% | +40.3% | — | +12.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -88.4% | -67.7% | -3.0% | +22.5% | +16.0% | +18.2% |
Valuation Metrics
Evenly matched — NAKA and DOCS and JPM each lead in 2 of 7 comparable metrics.
Valuation Metrics
At 15.9x trailing earnings, JPM trades at a 90% valuation discount to WELL's 153.1x P/E. Adjusting for growth (PEG ratio), DOCS offers better value at 0.40x vs KO's 2.38x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Market CapShares × price | $79M | $3.9B | $6.6B | $149.1B | $892.3B | $348.2B |
| Enterprise ValueMkt cap + debt − cash | $266M | $3.7B | $7.7B | $165.5B | $1.49T | $383.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.43x | 21.10x | 59.16x | 153.11x | 15.93x | 26.62x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 14.43x | — | 73.47x | 14.34x | 24.75x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.40x | — | — | 0.90x | 2.38x |
| EV / EBITDAEnterprise value multiple | — | 17.02x | 47.84x | 66.35x | 18.32x | 25.89x |
| Price / SalesMarket cap ÷ Revenue | 43.19x | 6.00x | 2.82x | 13.98x | 3.19x | 7.26x |
| Price / BookPrice ÷ Book value/share | 0.10x | 4.33x | 14.40x | 3.35x | 2.46x | 10.18x |
| Price / FCFMarket cap ÷ FCF | — | — | 89.56x | 52.36x | 8.85x | 65.76x |
Profitability & Efficiency
DOCS leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-85 for NAKA. DOCS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), WELL scores 7/9 vs NAKA's 2/9, reflecting strong financial health.
| Metric | ||||||
|---|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -84.8% | +19.4% | -2.5% | +3.5% | +15.9% | +41.1% |
| ROA (TTM)Return on assets | -56.5% | +16.5% | -0.6% | +2.3% | +1.3% | +13.1% |
| ROICReturn on invested capital | -42.1% | +19.8% | +8.6% | +0.5% | +4.5% | +15.8% |
| ROCEReturn on capital employed | -76.2% | +20.7% | +9.4% | +0.6% | +8.9% | +17.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 6 | 4 | 7 | 5 | 7 |
| Debt / EquityFinancial leverage | 0.41x | 0.01x | 2.34x | 0.49x | 2.60x | 1.33x |
| Net DebtTotal debt minus cash | $187M | -$209M | $1.0B | $16.3B | $599.0B | $35.2B |
| Cash & Equiv.Liquid assets | $23M | $219M | $229M | $5.0B | $343.3B | $10.3B |
| Total DebtShort + long-term debt | $210M | $10M | $1.3B | $21.4B | $942.4B | $45.5B |
| Interest CoverageEBIT ÷ Interest expense | -24.72x | — | — | 0.26x | 0.74x | 10.70x |
Total Returns (Dividends Reinvested)
Evenly matched — HIMS and WELL each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in WELL five years ago would be worth $27,819 today (with dividends reinvested), compared to $374 for NAKA. Over the past 12 months, WELL leads with a +43.3% total return vs NAKA's -99.3%. The 3-year compound annual growth rate (CAGR) favors HIMS at 50.8% vs NAKA's -66.6% — a key indicator of consistent wealth creation.
| Metric | ||||||
|---|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -72.3% | -52.2% | -9.7% | +14.6% | -0.9% | +18.6% |
| 1-Year ReturnPast 12 months | -99.3% | -63.0% | -49.5% | +43.3% | +20.3% | +17.7% |
| 3-Year ReturnCumulative with dividends | -96.3% | -36.1% | +242.8% | +175.6% | +133.8% | +42.6% |
| 5-Year ReturnCumulative with dividends | -96.3% | -61.0% | +150.0% | +178.2% | +120.7% | +63.1% |
| 10-Year ReturnCumulative with dividends | -96.3% | -61.0% | +207.9% | +229.1% | +475.6% | +118.2% |
| CAGR (3Y)Annualised 3-year return | -66.6% | -13.9% | +50.8% | +40.2% | +32.7% | +12.6% |
Risk & Volatility
KO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than NAKA's 2.88 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 96.3% from its 52-week high vs NAKA's 0.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.88x | 0.75x | 2.48x | 0.04x | 0.94x | -0.20x |
| 52-Week HighHighest price in past year | $679.20 | $76.51 | $70.43 | $221.68 | $337.25 | $84.04 |
| 52-Week LowLowest price in past year | $0.38 | $17.16 | $13.74 | $148.97 | $266.85 | $65.35 |
| % of 52W HighCurrent price vs 52-week peak | +0.7% | +27.0% | +42.8% | +96.0% | +94.7% | +96.3% |
| RSI (14)Momentum oscillator 0–100 | 35.4 | 40.8 | 51.5 | 55.6 | 65.0 | 60.8 |
| Avg Volume (50D)Average daily shares traded | 274K | 3.9M | 24.7M | 2.6M | 7.0M | 12.7M |
Analyst Outlook
KO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: NAKA as "Buy", DOCS as "Hold", HIMS as "Hold", WELL as "Buy", JPM as "Buy", KO as "Buy". Consensus price targets imply 77.0% upside for NAKA (target: $8) vs -10.5% for HIMS (target: $27). For income investors, KO offers the higher dividend yield at 2.52% vs WELL's 1.30%.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $8.00 | $29.47 | $27.00 | $239.11 | $339.75 | $86.13 |
| # AnalystsCovering analysts | 2 | 23 | 20 | 34 | 61 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +1.3% | +1.9% | +2.5% |
| Dividend StreakConsecutive years of raises | 0 | — | — | 2 | 15 | 56 |
| Dividend / ShareAnnual DPS | — | — | — | $2.76 | $5.95 | $2.04 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.4% | +11.2% | +1.4% | 0.0% | +3.9% | +0.2% |
DOCS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). KO leads in 2 (Risk & Volatility, Analyst Outlook). 2 tied.
NAKA vs DOCS vs HIMS vs WELL vs JPM vs KO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NAKA or DOCS or HIMS or WELL or JPM or KO a better buy right now?
For growth investors, Hims & Hers Health, Inc.
(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -33. 0% for Nakamoto Inc. (NAKA). JPMorgan Chase & Co. (JPM) offers the better valuation at 15. 9x trailing P/E (14. 3x forward), making it the more compelling value choice. Analysts rate Nakamoto Inc. (NAKA) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NAKA or DOCS or HIMS or WELL or JPM or KO?
On trailing P/E, JPMorgan Chase & Co.
(JPM) is the cheapest at 15. 9x versus Welltower Inc. at 153. 1x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Doximity, Inc. wins at 0. 28x versus The Coca-Cola Company's 2. 21x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — NAKA or DOCS or HIMS or WELL or JPM or KO?
Over the past 5 years, Welltower Inc.
(WELL) delivered a total return of +178. 2%, compared to -96. 3% for Nakamoto Inc. (NAKA). Over 10 years, the gap is even starker: JPM returned +475. 6% versus NAKA's -96. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NAKA or DOCS or HIMS or WELL or JPM or KO?
By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.
20β versus Nakamoto Inc. 's 2. 88β — meaning NAKA is approximately -1540% more volatile than KO relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — NAKA or DOCS or HIMS or WELL or JPM or KO?
By revenue growth (latest reported year), Hims & Hers Health, Inc.
(HIMS) is pulling ahead at 59. 0% versus -33. 0% for Nakamoto Inc. (NAKA). On earnings-per-share growth, the picture is similar: The Coca-Cola Company grew EPS 23. 6% year-over-year, compared to -1452. 2% for Nakamoto Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NAKA or DOCS or HIMS or WELL or JPM or KO?
Doximity, Inc.
(DOCS) is the more profitable company, earning 30. 4% net margin versus -28. 7% for Nakamoto Inc. — meaning it keeps 30. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 33. 3% versus -108. 2% for NAKA. At the gross margin level — before operating expenses — DOCS leads at 89. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NAKA or DOCS or HIMS or WELL or JPM or KO more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Doximity, Inc. (DOCS) is the more undervalued stock at a PEG of 0. 28x versus The Coca-Cola Company's 2. 21x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 3x forward P/E versus 73. 5x for Welltower Inc. — 59. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NAKA: 77. 0% to $8. 00.
08Which pays a better dividend — NAKA or DOCS or HIMS or WELL or JPM or KO?
In this comparison, KO (2.
5% yield), JPM (1. 9% yield), WELL (1. 3% yield) pay a dividend. NAKA, DOCS, HIMS do not pay a meaningful dividend and should not be held primarily for income.
09Is NAKA or DOCS or HIMS or WELL or JPM or KO better for a retirement portfolio?
For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
20), 2. 5% yield, +118. 2% 10Y return). Nakamoto Inc. (NAKA) carries a higher beta of 2. 88 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +118. 2%, NAKA: -96. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NAKA and DOCS and HIMS and WELL and JPM and KO?
These companies operate in different sectors (NAKA (Financial Services) and DOCS (Healthcare) and HIMS (Healthcare) and WELL (Real Estate) and JPM (Financial Services) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: NAKA is a small-cap quality compounder stock; DOCS is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; WELL is a mid-cap high-growth stock; JPM is a large-cap deep-value stock; KO is a large-cap quality compounder stock. WELL, JPM, KO pay a dividend while NAKA, DOCS, HIMS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.